Literature DB >> 35308690

Radiation Induced Abscopal Effect in a Patient With Malignant Pleural Mesothelioma on Pembrolizumab.

Rebekah Rittberg1,2, Elisa Chan3, Stephen Yip4, Deepu Alex5, Cheryl Ho1,2.   

Abstract

Abscopal effect is a rare phenomenon in which treatment benefit from radiotherapy (RT) is seen outside the target field due to activation of the immune system inducing an anti-tumor effect. This phenomenon has been reported in cancer patients receiving immune checkpoint inhibitors (ICI). Here we report a case of presumed abscopal effect in malignant mesothelioma. The patient received second-line single-agent pembrolizumab however had disease progression after four cycles leading to palliative RT (20 Gray) to the right mainstem bronchus. Follow-up radiographic imaging confirmed benefit and pembrolizumab was continued. Follow-up computed tomography (CT) five months after RT, showed marked radiographic improvement of all measurable diseases with improvement in right-sided aerated lung volume. Because of the original disease progression on pembrolizumab, with marked improvements within and outside the RT field after RT, treatment response was presumed due to the abscopal effect.
Copyright © 2022, Rittberg et al.

Entities:  

Keywords:  abscopal effect; immune modulation; immunotherapy; mesothelioma; pembrolizumab; radiotherapy

Year:  2022        PMID: 35308690      PMCID: PMC8920754          DOI: 10.7759/cureus.22159

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  17 in total

1.  First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Paul Baas; Arnaud Scherpereel; Anna K Nowak; Nobukazu Fujimoto; Solange Peters; Anne S Tsao; Aaron S Mansfield; Sanjay Popat; Thierry Jahan; Scott Antonia; Youssef Oulkhouir; Yolanda Bautista; Robin Cornelissen; Laurent Greillier; Francesco Grossi; Dariusz Kowalski; Jerónimo Rodríguez-Cid; Praveen Aanur; Abderrahim Oukessou; Christine Baudelet; Gérard Zalcman
Journal:  Lancet       Date:  2021-01-21       Impact factor: 79.321

Review 2.  Mesothelioma Biomarkers: Discovery in Search of Validation.

Authors:  Harvey I Pass; Marjan Alimi; Michele Carbone; Haining Yang; Chandra M Goparaju
Journal:  Thorac Surg Clin       Date:  2020-09-14       Impact factor: 1.750

Review 3.  The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado?

Authors:  D Xing; S Siva; G G Hanna
Journal:  Clin Oncol (R Coll Radiol)       Date:  2019-04-17       Impact factor: 4.126

4.  Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.

Authors:  Raffit Hassan; Anish Thomas; John J Nemunaitis; Manish R Patel; Jaafar Bennouna; Franklin L Chen; Jean-Pierre Delord; Afshin Dowlati; Samith T Kochuparambil; Matthew H Taylor; John D Powderly; Ulka N Vaishampayan; Claire Verschraegen; Hans Juergen Grote; Anja von Heydebreck; Kevin Chin; James L Gulley
Journal:  JAMA Oncol       Date:  2019-03-01       Impact factor: 31.777

Review 5.  Systematic review of case reports on the abscopal effect.

Authors:  Yazan Abuodeh; Puja Venkat; Sungjune Kim
Journal:  Curr Probl Cancer       Date:  2015-10-09       Impact factor: 3.187

6.  DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.

Authors:  Claire Vanpouille-Box; Amandine Alard; Molykutty J Aryankalayil; Yasmeen Sarfraz; Julie M Diamond; Robert J Schneider; Giorgio Inghirami; C Norman Coleman; Silvia C Formenti; Sandra Demaria
Journal:  Nat Commun       Date:  2017-06-09       Impact factor: 14.919

7.  Radiation-induced tumor immunity in patients with non-small cell lung cancer.

Authors:  Natalie A Lockney; Mei Zhang; Christopher G Morris; Romaine Charles Nichols; Paul Okunieff; Steven Swarts; Zhenhuan Zhang; Bingrong Zhang; Amy Zhang; Bradford S Hoppe
Journal:  Thorac Cancer       Date:  2019-06-22       Impact factor: 3.500

8.  Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab.

Authors:  Wambaka Ange Mampuya; Hasna Bouchaab; Niklaus Schaefer; Remy Kinj; Stefano La Rosa; Igor Letovanec; Mahmut Ozsahin; Jean Bourhis; George Coukos; Solange Peters; Fernanda G Herrera
Journal:  Clin Transl Radiat Oncol       Date:  2021-01-01

9.  Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.

Authors:  Dean A Fennell; Sean Ewings; Christian Ottensmeier; Raffaele Califano; Gerard G Hanna; Kayleigh Hill; Sarah Danson; Nicola Steele; Mavis Nye; Lucy Johnson; Joanne Lord; Calley Middleton; Peter Szlosarek; Sam Chan; Aarti Gaba; Liz Darlison; Peter Wells-Jordan; Cathy Richards; Charlotte Poile; Jason F Lester; Gareth Griffiths
Journal:  Lancet Oncol       Date:  2021-10-14       Impact factor: 41.316

Review 10.  Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.

Authors:  Katsuyuki Hotta; Nobukazu Fujimoto
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.